Share
Science For The Real World: Canadian Hematology Today
CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection
Season 1, Ep. 3
•
Sponsored by Bristol Myers Squibb.
More episodes
View all episodes
1. Prise en charge des patients atteints de LLC doublement exposée et réfractaire.
16:48||Season 2, Ep. 14. Addressing the management of patients with double exposed and refractory CLL
17:40||Season 1, Ep. 42. Practical considerations in the management of early rrMM in the Canadian context
32:00||Season 1, Ep. 2This podcast features Dr. Christopher Venner and his colleagues from the hematology community, Dr. Sylvia McCulloch, Dr. Arleigh McCurdy, and Dr. Chai Phua discussing the approach to the management of early rrMM in the Canadian context. This episode of Science for the Real World is part of Canadian Hematology Today, an open-access scientific journal for the hematology community.
1. The role of selinexor in early rrMM and sequencing in 2024.
27:34||Season 1, Ep. 1In this episode of "Science for the Real World: Canadian Hematology Today," Dr. Peter Anglin hosts a discussion with Dr. Joshua Richter and Dr. Darrell White on the management of early rrMM in 2024, focusing on the role of selinexor and treatment sequencing.